Want to see KIDS full AI Analyst Report?
Top Page
OrthoPediatrics
(NASDAQ:KIDS)
Select Model
Select Model
Rating:65Neutral
Price Target:
$27.00
▲(43.08% Upside)
Action:Reiterated
Date:08/05/26
The score is driven by strong technical momentum and a notably positive earnings update (raised revenue guidance, improving adjusted EBITDA, and a credible path toward free-cash-flow breakeven). These positives are tempered by weaker underlying financial performance (ongoing losses and negative free cash flow in TTM) and an unsupportive earnings-based valuation due to a negative P/E.
Positive Factors
Specialized Market Position
A pediatric-only focus, broad product portfolio and established hospital access create specialized expertise and surgeon relationships. This positioning can support adoption, recurring procedure demand and differentiation from larger adult-focused orthopedic competitors.
Negative Factors
Persistent Net Losses
The company has not yet translated high gross margins into sustainable operating or net earnings. Persistent losses constrain retained capital, weaken returns on equity and leave execution dependent on continued revenue growth and eventual cost leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized Market Position
A pediatric-only focus, broad product portfolio and established hospital access create specialized expertise and surgeon relationships. This positioning can support adoption, recurring procedure demand and differentiation from larger adult-focused orthopedic competitors.
Read all positive factors
OrthoPediatrics (KIDS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$644.91M
Dividend YieldN/A
Average Volume (3M)196.93K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth14.49%
EPS Growth6.68%
CountryUS
Employees602
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.68
Shares Outstanding26,109,789
10 Day Avg. Volume194,659
30 Day Avg. Volume196,931
Financial Highlights & Ratios
PEG Ratio-3.45
Price to Book (P/B)1.20
Price to Sales (P/S)1.76
P/FCF Ratio-26.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.88Price Target Upside42.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$266.98M
OrthoPediatrics Business Overview & Revenue Model
Company Description
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children...
How the Company Makes Money
OrthoPediatrics makes money primarily by selling pediatric orthopedic medical devices to healthcare providers. Its core revenue stream is product sales of implants (e.g., fixation and deformity correction systems) and the associated surgical instr...
OrthoPediatrics Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Positive
The call conveyed substantial positive momentum: record revenue, record adjusted EBITDA, strong T&D and OPSB growth, material free cash flow improvement, and raised revenue guidance. Challenges were largely timing-related (zero 7D units, Brazil set timing) and temporary foreign exchange headwinds that widened non-GAAP loss per share. Management emphasized disciplined capital allocation and conservatism in guidance while highlighting a multi-year product 'super cycle' that should drive higher-margin, higher-ASP sales over time. On balance, positive operational and financial improvements outweigh the notable but mostly timing- and FX-driven lowlights.Positive Updates
Record Patient Impact
Helped nearly 46,000 children in Q2 (a new record), raising cumulative patient impact to approximately 1.4 million.
Negative Updates
Scoliosis Revenue Decline (Timing Impact)
Scoliosis global revenue was $16.9M, down 9% year-over-year primarily due to timing items: zero 7D unit sales in Q2 (vs. multiple units in the comparable period) and significantly fewer scoliosis set sales into Brazil; management says excluding timing items scoliosis would have grown in the mid-teens.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Patient Impact
Helped nearly 46,000 children in Q2 (a new record), raising cumulative patient impact to approximately 1.4 million.
Read all positive updates
Company Guidance
OrthoPediatrics raised full‑year 2026 revenue guidance to $265–$269 million (up $2M, +12%–14% YoY) and reiterated adjusted EBITDA guidance of approximately $25 million; management expects to deploy roughly $10 million in sets (about $5M deployed to date, $2.9M in Q2 vs $4.6M in Q2 2025) and to achieve positive free cash flow in H2 2026 with full‑year free cash flow break‑even or better. The guidance is supported by Q2 record revenue of $70.5M (+15% YoY), record adjusted EBITDA of $6.8M (adjusted EBITDA margin ~10%), a Q2 gross margin of 74% (vs 72% LY), Q2 free cash flow used of $3.1M (an $10.8M, or 78%, improvement vs $13.9M in Q2 2025), first‑half adjusted EBITDA of $9M toward the $25M target, $47.9M in cash/short‑term investments/restricted cash, and $20M of term‑loan availability, with management noting seasonal variability but high confidence in the outlook.OrthoPediatrics Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 252.72M | 236.35M | 204.73M | 148.73M | 122.29M | 98.05M |
| Gross Profit | 186.14M | 172.66M | 148.60M | 111.25M | 90.66M | 73.40M |
| EBITDA | -10.25M | -11.94M | -20.23M | -8.38M | -8.69M | -7.19M |
| Net Income | -39.73M | -39.65M | -37.82M | -20.97M | 1.26M | -16.26M |
Balance Sheet | ||||||
| Total Assets | 511.39M | 508.63M | 473.21M | 438.75M | 427.73M | 308.40M |
| Cash, Cash Equivalents and Short-Term Investments | 45.88M | 60.85M | 68.83M | 80.31M | 118.29M | 54.91M |
| Total Debt | 91.59M | 99.99M | 80.90M | 10.06M | 907.00K | 28.51M |
| Total Liabilities | 167.77M | 162.03M | 118.64M | 61.72M | 49.08M | 83.03M |
| Stockholders Equity | 343.61M | 346.60M | 354.57M | 377.02M | 378.65M | 225.37M |
Cash Flow | ||||||
| Free Cash Flow | -1.83M | -15.96M | -41.31M | -46.03M | -31.80M | -29.07M |
| Operating Cash Flow | 7.41M | -4.85M | -27.05M | -27.05M | -21.77M | -13.06M |
| Investing Cash Flow | -32.88M | -43.63M | -13.16M | 41.68M | -113.37M | -7.41M |
| Financing Cash Flow | -2.05M | 23.98M | 53.13M | 7.30M | 135.97M | 6.00K |
OrthoPediatrics Technical Analysis
Positive
18.87
Price Trends
20.33
Positive
18.58
Positive
18.06
Positive
Market Momentum
1.50
Negative
79.65
Negative
91.14
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KIDS, the sentiment is Positive. The current price of 18.87 is below the 20-day moving average (MA) of 21.94, below the 50-day MA of 20.33, and above the 200-day MA of 18.06, indicating a bullish trend. The MACD of 1.50 indicates Negative momentum. The RSI at 79.65 is Negative, neither overbought nor oversold. The STOCH value of 91.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KIDS.
OrthoPediatrics Risk Analysis
OrthoPediatrics disclosed 79 risk factors in its most recent earnings report. OrthoPediatrics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
OrthoPediatrics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.17B | 18.09 | 28.39% | ― | 3.14% | ― | |
65 Neutral | $644.91M | -14.70 | -11.53% | ― | 14.49% | 6.68% | |
59 Neutral | $778.06M | 35.16 | 4.60% | ― | 5.31% | ― | |
55 Neutral | $408.55M | -6.53 | -14.05% | ― | 2.99% | 51.77% | |
54 Neutral | $1.55B | -23.96 | -45.97% | ― | 3.92% | 70.03% | |
52 Neutral | $292.66M | -4.84 | -74.06% | ― | -3.95% | -17.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
KIDS
OrthoPediatrics
25.50
6.37
33.30%
OFIX
Orthofix Medical
10.22
-4.28
-29.52%
TNDM
Tandem Diabetes Care
23.73
12.84
117.91%
VREX
Varex Imaging
18.46
7.19
63.80%
BVS
Bioventus
14.30
6.98
95.36%
TMCI
Treace Medical Concepts
4.45
-2.74
-38.11%
OrthoPediatrics Corporate Events
Business Operations and StrategyFinancial Disclosures
OrthoPediatrics Highlights Growth in 2026 Investor Presentations
Positive
Aug 4, 2026
OrthoPediatrics’ executive officers plan upcoming presentations to investors and analysts using a new 2026 investor deck that highlights the company’s pediatric-only focus and outlines its use of non-GAAP metrics such as free cash flow...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
OrthoPediatrics shareholders approve directors and incentive plan
Positive
Jun 4, 2026
At its June 4, 2026 annual meeting, OrthoPediatrics shareholders elected four directors, George S. M. Dyer, Kelly Fischer, David R. Pelizzon, and Harald Ruf, to serve terms running until the 2029 annual meeting or until successors are chosen. Inve...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.